the aclaris therapeutics ( n=10 ) company is a biopharmaceutical company focused on dermatology. we have recently initiated a phase 3 trial of a-101 45% and we have recently completed our first in human single ascending and multiple ascending dose trial with ATI-450 in oral small molecule microkinesia ( mk2 ) inhibitor for the treatment of immuno-inflammatory diseases. we continue to advance our additional novel kinase inhibitors, ATI-1777 and atii-2138, and we will continue to advance our additional novel kinases inhibitors. we will continue to advance our additional novel  Kinase inhibitors, i-1777 and ik/txk/jak3 towards atopic derm submissions.